43
EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012

Epidemiology of heme malignancies

  • Upload
    marly

  • View
    65

  • Download
    0

Embed Size (px)

DESCRIPTION

Epidemiology of heme malignancies. Julie Kasperzyk , ScD January 11, 2012. Background. Global Cancer Frequency. Roman & Smith Histopathology 2011, 58, 4–14. Definition: Hematological malignancies. Group of cancers that affect the blood, lymph nodes, and bone marrow - PowerPoint PPT Presentation

Citation preview

Page 1: Epidemiology of  heme  malignancies

EPIDEMIOLOGY OF HEME MALIGNANCIES

Julie Kasperzyk, ScDJanuary 11, 2012

Page 2: Epidemiology of  heme  malignancies

Background

Page 3: Epidemiology of  heme  malignancies

Roman & Smith Histopathology 2011, 58, 4–14.

Global Cancer Frequency

Page 4: Epidemiology of  heme  malignancies

Definition: Hematological malignancies Group of cancers that affect the blood,

lymph nodes, and bone marrow Account for ~9% of new cancer

diagnoses in the US 3 major groups

Leukemia: starts in bone marrow and spreads to blood/periphery

Lymphoma: occurs in lymphoid tissue Plasma cell neoplasms (e.g. multiple

myeloma)

Page 5: Epidemiology of  heme  malignancies

Overview of blood cells

Page 6: Epidemiology of  heme  malignancies

All heme malignancies

(100%)Leukemi

a(~40%)

Acute Lymphocytic (ALL): most common childhood leukemia

Chronic Lymphocytic (CLL): most common leukemia in elderly

Acute Myeloid (AML)

Chronic Myeloid (CML): more common in adults, rare in children

Other leukemias

Lymphoma

(~50%)Non-Hodgkin lymphoma (NHL): many histological subtypes, more common than HLHodgkin lymphoma (HL): morphologically distinct Reed-Sternberg cells

Plasma Cell

Neoplasm(~10%)Multiple myeloma (MM)

Other

Page 7: Epidemiology of  heme  malignancies

Global lymphoma incidence

Page 8: Epidemiology of  heme  malignancies

Multiple myeloma

Hodgkin lymphoma

Non-Hodgkin lymphoma

Leukemia

0 2 4 6 8 10 12 14

Northern AmericaLatin AmericaAsiaAfrica

Per 100,000

Age-standardized rates of heme cancers in selected regions

GLOBOCAN 2008, IARC

Page 9: Epidemiology of  heme  malignancies

Surveillance, Epidemiology and End Results (SEER) Program. A source for US cancer statistics.

Heme cancer incidence rates in the US from 1975-2007

Page 10: Epidemiology of  heme  malignancies

Heme cancer mortality rates in the US from 1975-2007

Page 11: Epidemiology of  heme  malignancies

www.lls.org

Page 12: Epidemiology of  heme  malignancies

Leukemia

Page 13: Epidemiology of  heme  malignancies

Acute vs. chronic Acute

Elevated immature blood cells in the marrow and blood

Rapid progression and accumulation of malignant cells Requires immediate treatment ALL is most common form of leukemia in children

Chronic Elevated mature (or relatively mature) blood cells Takes months to years to progress Sometimes treated conservatively (esp. low-grade) Mostly occurs at older ages

Page 14: Epidemiology of  heme  malignancies

Number of new cases & deaths in US, 2010

ALL

AML

CLL CML

Other/u

nclass

ified

02000400060008000

10000120001400016000

New CasesDeaths

Page 15: Epidemiology of  heme  malignancies

Rates of Acute Leukemia (ALL & AML) by age and sex, US

ALL AML

Page 16: Epidemiology of  heme  malignancies

ALL Can involve B (~85%) or T (~15%)

lymphocytes, rarely natural killer cells Risk factors largely unknown

Ionizing radiation Higher rates found in more developed

countries and families with higher SES 5-year survival

66% for all ages 91% for children under 5 yrs

www.lls.org

Page 17: Epidemiology of  heme  malignancies

AML Involves myeloid progenitor cells Potential risk factors:

Chronic benzene exposure (found in cigarette smoke)

Certain genetic disorders Down syndrome increased risk of AML

Past chemo or radiation therapy History of other blood cancers or disorders

5-year survival 24% for all ages 61% for children under 15 yrs

www.lls.org

Page 18: Epidemiology of  heme  malignancies

Rates of Chronic Leukemia (CLL & CML) by age and sex, US

CLL CML

Page 19: Epidemiology of  heme  malignancies

CLL Most common type of leukemia in adults Begins in the bone marrow and can progress

either slowly or quickly depending on subtype 95% are B lymphocyte origin, with remaining

5% either T cell or natural killer cell origin Risk factors

Family history (1st degree relatives of CLL cases are 3-4x more likely to develop CLL than people without family Hx)

Vietnam veterans (agent orange exposure) 5-year survival: 80% for all ages

Page 20: Epidemiology of  heme  malignancies

CML Involves proliferation of mature and

immature myeloid cells, accumulate in bone marrow and blood

Potential risk factors Ionizing radiation Radiation therapy from treatment of other

cancers 5-year survival: 55% for all ages

Page 21: Epidemiology of  heme  malignancies

CML and the Philadelphia chromosome

Translocation between BCR and c-ABL

BCR-ABL acts as a tyrosine kinase, and constitutive expression increases rate of mitosis and decreases apoptosis

Treated with tyrosine kinase inhibitors (eg Gleevec) which has dramatically improved survival

http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/C/CML.html

Page 22: Epidemiology of  heme  malignancies

Leukemia rates by race/ethnicity, US

Source: SEER

Page 23: Epidemiology of  heme  malignancies

Atomic bomb survivors

J Radiat Res (Tokyo). 1991 Dec;32 Suppl 2:54-63.

Page 24: Epidemiology of  heme  malignancies

Treatments for leukemia Depends on subtype and risk factors Multi-drug chemotherapy regimen Less common: radiation therapy or bone

marrow transplant Consequence if untreated: disruption of

normal blood production Anemia: caused by low levels of RBC production Neutropenia: more susceptible to infections due

to low numbers of neutrophils (a type of WBC) Bleeding/bruising: caused by low platelet levels

Page 25: Epidemiology of  heme  malignancies

Lymphoma

Page 26: Epidemiology of  heme  malignancies

Non-Hodgkin (NHL) & Hodgkin (HL) Affect the lymphatic system NHL: Mostly (~85%) B-cell origin, and

remaining 15% T-cell or natural killer cell origin

HL: B-cell origin Major risk factors

Male gender Caucasian race Immunodeficiency syndromes (acquired and

inherited)

Page 27: Epidemiology of  heme  malignancies

Lymphoma subtype frequencies

Roman & Smith Histopathology 2011, 58, 4–14.

Hodgkin lymphoma subtypes

Source: Haematological Malignancy Research Network, 2004-2009

Page 28: Epidemiology of  heme  malignancies

New Cases Deaths0

10000

20000

30000

40000

50000

60000

70000

NHLHL

Number of new cases & deaths in US, 2010

Page 29: Epidemiology of  heme  malignancies

Rates of NHL & HL by age, US

Page 30: Epidemiology of  heme  malignancies

Rates of NHL & HL by age and sex, US

Page 31: Epidemiology of  heme  malignancies

Rates over time of NHL & HL by race/ethnicity, US

NHL HL Source: SEER

Page 32: Epidemiology of  heme  malignancies

Epstein-Barr Virus (EBV) Herpesvirus family Infects nasopharyngeal epithelial cells

and B lymphocytes Promotes proliferation of infected cells

Ubiquitous in human populations worldwide Childhood infections are generally mild Adolescent/adult infection can lead to

mononucleosis

Page 33: Epidemiology of  heme  malignancies

EBV & Burkitt lymphoma Rare, aggressive NHL with B-cell origin Endemic in regions of Africa where Epstein-Barr

virus (EBV) and malaria are common Malaria causes T cell immunodeficiency

Occurs typically in young children, beginning in the lymph nodes in the neck

Nearly 100% of tumors from African Burkitt’s lymphoma carry the EBV genome and express EBV-encoded antigens

Other types (weakly linked to EBV): sporadic (non-African) immunodeficiency-associated

Page 34: Epidemiology of  heme  malignancies

EBV & HL ~1/3 of tumors positive for EBV in

developed countries 2- to 3- fold increased HL risk with

history of infectious mononucleosis Hygiene hypothesis

Lower risk with daycare, higher birth order, larger sibship size

Mueller & Grufferman. Hodgkin Lymphoma in Cancer Epidemiology and Prevention. 3rd edition.

Page 35: Epidemiology of  heme  malignancies

HTLV-1 & adult T-cell leukemia/lymphoma (ATLL)

Human T-lymphotropic virus type 1 (HTLV-1) Endemic to Japan, Caribbean, & parts of

Central Africa Immortalizes infected T-cells (similar to

HIV) HTLV-1 is a necessary but not sufficient

cause of ATLL ~3% of infected individuals develop ATLL

Page 36: Epidemiology of  heme  malignancies

HIV & lymphoma HIV weakens the

immune system More susceptible to

other infectious agents (e.g. EBV) that increase lymphoma risk

Introduction of antiretroviral therapy has reduced incidence of NHL among HIV-infected individuals

Engels et al. Int J Cancer. 2008;123:187-94.

Page 37: Epidemiology of  heme  malignancies

Treatment for lymphoma Primarily chemotherapy and radiation therapy In some cases: bone marrow transplant or

immunotherapy 5-year survival rate in US

NHL 1960-1963 (Caucasians only): 31% 1999-2006 (all races): 69%

HL 1960-1963 (Caucasians only): 40% 1999-2006 (all races): 88% Persons <20 yrs old: 96%

Page 38: Epidemiology of  heme  malignancies

Multiple Myeloma

Page 39: Epidemiology of  heme  malignancies

MM Cancer of plasma cells (mature B

lymphocytes), amass primarily in the bone marrow

Risk factors Male gender African American race/ethnicity History of MGUS (monoclonal gammopathy of

unknown significance) Environmental exposures (Agent Orange,

smoking, radiation, pesticides) Obesity

www.lls.org

Page 40: Epidemiology of  heme  malignancies

Rates of MM by age and sex, US

Page 41: Epidemiology of  heme  malignancies

Rates over time of MM by race/ethnicity, US

Source: SEER

Page 42: Epidemiology of  heme  malignancies

Obesity & MM

RR for obesity vs. normal weight

Overall: RR=1.21

Wallin & Larssen. European Journal Of Cancer 2011;47:1606-15.

Page 43: Epidemiology of  heme  malignancies

Treatment for multiple myeloma Drug therapy (including chemotherapy),

stem cell transplantation, radiation therapy

5-year survival 1960-1963 (Caucasians only): 12% 1999-2006 (all races): 39%